Protective Capacity of Monoclonal Antibodies against Acinetobacter baumannii K9 Capsular Polysaccharide-Reference-Cited by-同舟云学术

Protective Capacity of Monoclonal Antibodies against Acinetobacter baumannii K9 Capsular Polysaccharide

Published:2023-02-14 Issue:1 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Karatovskaya Anna¹,Rudenko Natalia¹^ORCID,Zamyatina Anna¹,Zvonarev Anton²,Oleinikov Vladimir³,Shpirt Anna⁴,Perepelov Andrei⁴,Knirel Yuriy⁴,Brovko Fedor¹^ORCID

Affiliation:

1. Laboratory of Immunochemistry, Pushchino Branch, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Moscow Region, Russia

2. FSBIS FRC Pushchino Scientific Centre of Biological Research, G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Russian Academy of Sciences, Pushchino, Moscow Region, Russia

3. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Ulitsa Miklukho-Maklaya, Moscow, Russia

4. Laboratory of Carbohydrates and Biocides, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia

Abstract

MAbs detected A. baumannii in infected lung tissue, effectively opsonized bacteria, and protected model animals from infection.

Funder

Russian Science Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.04141-22

Reference21 articles.

1. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study

2. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit

3. Current advances and challenges in the development ofAcinetobactervaccines

4. Serum therapy;Park WH;Bull N Y Acad Med,1931

5. Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens